Revelation Biosciences, Inc. Announces Financial Results

REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026 SAN DIEGO – November 5, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developi

Event · Earnings
Original reporting
Published Nov 5, 2026, 10:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$REVB
Bearish
high confidence
Mentioned
$REVB
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$REVBBearishLow
01

Why it matters

The disclosed financials underscore higher operating losses and a cash runway that may limit near‑term trial progress.

02

Market read

First‑time disclosure of Q3 results for a micro‑cap biotech; informs short‑term pricing and liquidity considerations.

03

What to watch

Potential partnership with a CRO and a $94 B TAM estimate for Gemini may support future upside despite short‑term weakness.

Relevance 7/10Novelty 7/10Timing: post‑market today

Background

Revelation Biosciences is a clinical‑stage life‑sciences firm developing the TLR4 agonist Gemini for kidney injury and other inflammatory conditions.

Company-level read

Ticker impact

$REVBBearishHigh confidence
Context

SEC 8‑K disclosed Revelation Biosciences' Q3 and nine‑month results, showing a net loss of $3.3 M and cash sufficient only to Q2 2027.

Expected impact

likely pressure as investors price in higher loss and cash constraints

Evidence & confidence

Loss per share widened dramatically and cash balance fell 15%, raising concerns about liquidity and execution risk.

Market effects

Biotech sector may see modest pullback as micro‑cap earnings highlight cash‑burn risks.

Limited to U.S. small‑cap biotech investors.

Low; the company is micro‑cap with niche therapeutic focus.

Counterpoint

If Gemini's addressable market materializes, the current loss could be viewed as a long‑term investment in pipeline value.

Key entities

  • James Rolke

    Chief Executive Officer of Revelation Biosciences.

Related articles

$REVBMedAI 8/10

Revelation Aiming for Paradigm Shift in Kidney Disease Care

Revelation Biosciences (REVB) is developing Gemini, a drug candidate for acute and chronic kidney disease, post-surgical infections, and severe burns. The company plans to launch a Phase 2/3 study for acute kidney injury later this year, with completion expected in about two years. CEO James Rolke highlights Gemini's potential to reduce inflammation and prevent scar tissue, citing positive pre-clinical and early clinical results. Revelation aims to submit Gemini for FDA approval if the study mee

$REVBMed

Revelation Biosciences, Inc. Announces Financial Results

REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Six Months Ended June 30, 2026 SAN DIEGO – August 6, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innov

$XPMedAI 8/10

XP Q3 2026 slides: asset growth strong, but margin pressure evident

XP Inc. reported Q3 2026 earnings with total client assets up 15% YoY to R$2.2T, but net margins contracted to 26.9%. Revenue grew 8% YoY to R$5.3B, while SG&A expenses rose 12% YoY. Shares fell 4.26% post-earnings. The company is diversifying revenue, with non-investment revenues now 20% of retail revenue. Management expects 10% annual top-line growth in 2027.

$LUVUMed

Luvu Brands, Inc.: Luvu Brands Reports First Quarter Fiscal 2027 Results: 10% Net Sales Growth, Wholesale Sales Up 12%

Luvu Brands (LUVU) reported Q1 FY2027 results with net sales up 10% to $6.78M, wholesale sales up 12.3% to $4.72M, and direct-to-consumer sales up 5.3% to $2.06M. Gross profit fell 10.1% to $1.78M due to higher freight and labor costs, resulting in an operating loss of $332K and a net loss of $365K. Cash from operations increased to $120K, and cash reserves were $1.02M.